2796997-12-9
2796997-12-9
Chemical Structure
Biological Activity: PF-06835375 is a selective, humanized CXCR5-targeting immunoglobulin G1 antibody. PF-06835375 depletes CXCR5-positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
PF-06835375 | 97.71% | PF-06835375 is a selective, humanized CXCR5-targeting immunoglobulin G1 antibody. PF-06835375 depletes CXCR5-positive B cells, follicular helper T cells and circulating Tfh-like cells. PF-06835375 is applicable to research related to autoimmune diseases. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Zucchi D, et al. Systemic lupus erythematosus: one year in review 2023. Clin Exp Rheumatol. 2023;41(5):997-1008. [Content Brief]
- [2]. Cohen S, et al. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis. Arthritis Res Ther. 2024 Jun 6;26(1):117. [Content Brief]
